Edition:
United Kingdom

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

18.89USD
18 Jan 2018
Change (% chg)

$-0.96 (-4.84%)
Prev Close
$19.85
Open
$19.89
Day's High
$19.89
Day's Low
$18.88
Volume
81,442
Avg. Vol
92,170
52-wk High
$22.31
52-wk Low
$14.36

Latest Key Developments (Source: Significant Developments)

Macrogenics Enters Research Collaboration With Roche
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Macrogenics Inc ::MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE.MACROGENICS INC - UNDER TERMS OF AGREEMENT, ROCHE WILL PAY MACROGENICS AN UPFRONT PAYMENT OF $10 MILLION.MACROGENICS INC - MACROGENICS WILL ALSO BE ELIGIBLE TO RECEIVE UP TO $370 MILLION IN POTENTIAL MILESTONE PAYMENTS AND ROYALTIES ON FUTURE SALES.MACROGENICS INC - FURTHER DETAILS ABOUT TRANSACTION ARE NOT DISCLOSED.MACROGENICS INC - ENTERED INTO A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC..  Full Article

Incyte and MacroGenics announce global collaboration and licensing agreement
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Incyte Corp :Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012.MacroGenics inc - ‍Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications​.MacroGenics Inc - ‍upon closing, Incyte will pay MacroGenics an upfront payment of $150 million​.MacroGenics - ‍co is eligible to receive up to $420 million in potential development, regulatory milestones, up to $330 million in potential commercial milestones​.MacroGenics Inc - ‍MacroGenics retains right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012​.MacroGenics Inc - ‍MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018​.MacroGenics - ‍if MGA012 approved & commercialized, co will be eligible to get royalties, tiered from 15 percent to 24 percent, on future sales by Incyte​.  Full Article

First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics
Tuesday, 10 May 2016 

MacroGenics Inc : Commencement of phase 1 study triggers a $2 million milestone payment to MacroGenics under companies' October 2010 agreement. . Pfizer recently dosed a first patient in phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3 .First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics.  Full Article

BRIEF-Macrogenics Enters Research Collaboration With Roche

* MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE